Contineum Therapeutics, Inc. CTNM
We take great care to ensure that the data presented and summarized in this overview for Contineum Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CTNM
Top Purchases
Top Sells
About CTNM
Insider Transactions at CTNM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Daniel S. Lorrain Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,010
-0.6%
|
$16,160
$16.02 P/Share
|
|
Nov 18
2024
|
Daniel S. Lorrain Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,190
-1.76%
|
$99,040
$16.71 P/Share
|
|
Aug 13
2024
|
Stephen L. Huhn CMO & Sr VP, Clinical Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+50.0%
|
$12,800
$1.01 P/Share
|
|
Apr 09
2024
|
Versant Venture Capital Vi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
542,628
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
555K
Shares
From
2
Insiders
| Conversion of derivative security | 543K shares |
|---|---|
| Exercise of conversion of derivative security | 12.8K shares |
Sell / Disposition
7.2K
Shares
From
1
Insiders
| Open market or private sale | 7.2K shares |
|---|